E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Obstructive Pulmonary Disease (COPD) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•Compare the bronchodilator profile over 24 hours of tiotropium bromide administered either twice daily (2.5µg b.i.d.) or once daily (5µg q.d.) following 14 days treatment, measured in terms of 24h FEV1 AUC |
|
E.2.2 | Secondary objectives of the trial |
•Explore the bronchodilator efficacy of once daily versus twice daily dosing with tiotropium bromide at various time points following 14 days treatment, and on the first day of treatment. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure. 2. Patients with moderate to severe COPD (Stage II or Stage III) according to the GOLD Guidelines 2007. 3. Current or ex-smokers who have smoking history of at least 10 pack years. (Ten pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.) 4. Patients with a post-bronchodilator FEV1 ≥30% and < 80% of the predicted normal, and post-bronchodilator FEV1/FVC < 0.7 at Visit 1 and Visit 3
|
|
E.4 | Principal exclusion criteria |
1. Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy test). 2. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m, OR have past 6 weeks from surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: • surgical sterilization (e.g., bilateral tubal ligation), • hormonal contraception (implantable, patch, oral), and copper coated IUD. • At the discretion of the investigator, total abstinence is acceptable in cases where the age, career, lifestyle, or sexual orientation of the subject ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. NOTE: Reliable contraception should be maintained throughout the study 3. Patients requiring oxygen therapy on a daily basis for chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to Visit 1 or between Visit 1 and Visit 3. 4. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1. Patients who develop a respiratory tract infection or COPD exacerbations during the screening period (up to Visit 4) will not be eligible, but will be permitted to be re-screened at a later date (at least 6 weeks after the resolution of the respiratory tract infection). 5. Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to): • unstable ischemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding stable AF) • long term prednisone therapy (defined as ≥10 mg daily for at least 1 month prior to Visit 1) • history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. • narrow-angle glaucoma • symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention • uncontrolled hypo- and hyperthyroidism, hypokalemia, hyperadrenergic state • any condition which might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study 6. Patients with a history of asthma indicated by (but not limited to) onset of symptoms prior to age 40 years. 7. Patients contraindicated for tiotropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents. 8. Patients with a history of untoward reactions to sympathomimetic amines or inhaled medication or any component thereof. 9. Patients with a history of long QT syndrome or whose QTc measured at Visit 1 (Fridericia method) is prolonged (>450 ms for males or >470 for females). 10. Treatments for COPD and allied conditions: the following medications should not be used between Visits 1 and 11. The minimum washout prior to Visit 2 (Day -2) is specified below: • The long acting anticholinergic agent tiotropium:7 days. • Short acting anticholinergics: 8 h • Fixed combinations of β2-agonists and inhaled corticosteroids: 48 hours. (Subjects taking fixed combinations of beta2-agonists and inhaled corticosteroids should must be switched to the equivalent inhaled corticosteroid as monotherapy plus salbutamol as rescue therapy at least 48 hours prior to Visit 2) • Long-acting beta2-agonists: 48 h • Short acting beta2-agonists (other than those prescribed in the study): 6 h • Theophylline (any formulation): 7 days • Combinations of inhaled anticholinergics and beta2-agonists: 24 hours 11. Patients who need the following treatments for COPD and allied conditions unless they have been stabilized for at least one month prior to visit 1: • Cromoglycate, nedocromil, ketotifen, inhaled corticosteroids in recommended and constant doses and dose regimens 12. Patients taking β blocking agents 13. Patients unable to use the Respimat® device or a pMDI (rescue medication) or perform spirometry measurements. 14. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of Visit 1, whichever is longer. Participation in any clinical investigation within four (4) weeks prior to initial dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
FEV1 variability over 24 hours |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
study drug at different frequency of dosing |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 4 |